CD274 and esophageal cancer: Concerning the conventional reliable markers in immunotherapy of esophageal cancer, PD-L1 immunohistochemical evaluation results revealed that it hardly accurately predicted the therapeutic response to anti-PD-1 antibody in esophageal cancer patients (Yang et al., 2020a).